<DOC>
	<DOCNO>NCT01162421</DOCNO>
	<brief_summary>A Canadian study evaluate early use adalimumab methotrexate failure early rheumatoid arthritis . The study hypothesis verify adalimumab effectively reduce joint damage participant introduce earlier current practice .</brief_summary>
	<brief_title>A Canadian Study Evaluate Early Use Adalimumab After Methotrexate Failure Early Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subject diagnosis Rheumatoid Arthritis define 1987revised American College Rheumatologyclassification criterion disease duration le 2 year diagnosis . 2 . Subject must dose methotrexate therapy either subcutaneously orally administer ( 1525 mg/week ) least 3 month prior baseline visit inadequate response treatment define Disease Activity Score DAS28 &gt; 3.2 ( Screening visit ) . 3 . Subject must also meet follow three criterion ( screen visit ) : least 4 swollen joint 66 assess ; least 4 tender joint 68 assess ; subject must elevate erythrocyte sedimentation rate &gt; /= 20 mm/1h Creactive protein &gt; upper limit normal . 4 . Subject must fulfill least one follow three criterion : history rheumatoid factor positive ; history least one erosion Xray magnetic resonance imaging ; history anticycliccitrullinated protein antibody positive . 1 . Subject previous exposure biologic therapy include adalimumab . 2 . Prior diseasemodifying antirheumatic drug triple therapy methotrexate . 3 . Subject treat intraarticular parenteral administration corticosteroid precede 4 week prior baseline visit . Inhaled corticosteroid stable medical condition allow . 4 . Subject undergone joint surgery within precede two month ( joint assess within study ) Baseline . 5 . Subject poorly control medical condition , uncontrolled diabetes , unstable heart disease , congestive heart failure , recent cerebrovascular accident condition , opinion Investigator , would put subject risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anti-Inflammatory</keyword>
	<keyword>Biological Therapy</keyword>
	<keyword>adalimumab</keyword>
	<keyword>Disease-Modifying Antirheumatic Drugs</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Agents</keyword>
</DOC>